HJBC/iStock Editorial via Getty Images
- The U.S. Food and Drug Administration (FDA) has approved Wayrilz, a Bruton’s tyrosine kinase (BTK) inhibitor developed by Sanofi (NASDAQ:SNY), as a treatment for a bleeding disorder known as immune thrombocytopenia (ITP).
- Accordingly, the oral treatment currently under review for ITP
